Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2
- 14 June 2002
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (7) , 579-586
- https://doi.org/10.1038/sj.cgt.7700471
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazinesBioorganic & Medicinal Chemistry Letters, 2000
- Effect of the breast-cancer resistance protein on atypical multidrug resistanceThe Lancet Oncology, 2000
- A Family of Drug Transporters: the Multidrug Resistance-Associated ProteinsJNCI Journal of the National Cancer Institute, 2000
- A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1Cancer Gene Therapy, 2000
- Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXRCancer Letters, 1999
- Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 CellsJNCI Journal of the National Cancer Institute, 1999
- Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell LinesJNCI Journal of the National Cancer Institute, 1999
- A multidrug resistance transporter from human MCF-7 breast cancer cellsProceedings of the National Academy of Sciences, 1998
- Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozymeBritish Journal of Cancer, 1994